Global Opioid Use Disorder Market Report to 2031 – Featuring Alkermes, AstraZeneca, BioDelivery Sciences International and Camurus Among Others – ResearchAndMarkets.com

Global Opioid Use Disorder Market Report to 2031 - Featuring Alkermes, AstraZeneca, BioDelivery Sciences International and Camurus Among Others - ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Opioid Use Disorder Market By Drug Type, By Age group, By Route of Administration, By Distribution channel: Global Opportunity Analysis and Industry Forecast, 2021-2031” report has been added to ResearchAndMarkets.com’s offering.

The global opioid use disorder market was valued at $196.2 million in 2021, and is projected to reach $385.8 million by 2031, registering a CAGR of 7.1% from 2022 to 2031.

Opioid is a class of pain relievers that includes substances, which relax muscles and alleviate pain & stress. Prescription opioids are used to treat moderate-to-severe pain such as hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other pharmaceutical opioids. Opioid usage disorder (OUD) is a chronic, relapsing brain disorder that is characterized by obsessive opioid seeking and use despite negative effects.

Opioids use disorder is regarded as brain disorder because it involves functional alterations to brain circuits involved in motivation, stress, self-control, and decision-making, and those changes may persist for a long period after drug use has stopped. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued.

The opioids use disorder market is driven by increase in number of patients suffering from wide range of severe and chronic diseases such as cancer, cardiovascular disease, pain arising from injuries and other conditions. For instance, according to World Cancer Research Fund International, in 2020, around 18,094,716 new cancer cases diagnosed over the globe. As per the same source Breast and lung cancers were the most common cancers worldwide, 2,261,419 breast cancer and 2,206,771 lung cancer new cases diagnosed over the globe.

Thus, rise in number of cancer cases cause increase in incidence of surgeries. Surge in number of surgical procedures cause rise in use of opioid drugs to relieve post-surgical pain. Therefore, this factor can cause addiction of opioid drugs in patients. Thus, this factor is anticipated to drive the growth of opioids use disorder market.

Moreover, according to the Journal of JAMA Netw Open, in December 2021, around 5. 9 million population were reported to have undergone surgical procedure in the Rest of LAMEA In addition, according to Canadian Joint Replacement Registry (CJRR), approximately more than 75,000 knee replacement and 63,000 hip replacement surgeries were performed in the Canada from 2019 to 2020. As per the same source the knee and hip replacement surgery is the second most common surgery in Canada. This report also states 2.4% increase in the hip replacement surgery from 2019 to 2020.

In addition, increase in consideration of buprenorphine patches as an effective treatment mode to propel opioids use disorder market growth. The increase in use of buprenorphine patches as a successful treatment for opioid use disorder is one of the anticipated trends in the global market for treating opioid addiction. The use of buprenorphine patches is regarded as a cutting-edge strategy for treating opioid use disorder. Transdermal patches are a more pleasant drug delivery method that successfully lowers pain and can be self-administered by the patient than conventional therapy modalities such as injections.

These buprenorphine patches can also serve as a potential substitute for people who need immediate treatment for opioid use disorder. In addition, governments globally have increased the expenditure on the healthcare sector.

Key Benefits

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioid use disorder market analysis from 2021 to 2031 to identify the prevailing opioid use disorder market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the opioid use disorder market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global opioid use disorder market trends, key players, market segments, application areas, and market growth strategies.

Key Market Players

Alkermes, Inc.

AstraZeneca plc

BioDelivery Sciences International Inc.

braeburn pharmaceuticals

Camurus

Dr Reddy Laboratories Ltd

Pear Therapeutics

Hikma Pharmaceuticals PLC

mallinckrodt pharmaceuticals

NYC Health Hospitals

Orexo AB

OREXO AB

Indivior PLC

Reckitt Benckiser Pharmaceuticals Inc

Sandoz

Titan Pharmaceuticals, Inc.

Viatris Inc

Key Market Segments

By Drug Type

Agonist

Type

Methadone

Buprenorphine

Antagonist

By Age group

19 to 39

40 to 59

Age 60 and over

By Route of Administration

Oral

Intravenous

Sublingual

By Distribution channal

Hospital pharmacy

Retail Pharmacy

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

China

Japan

India

Australia

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

For more information about this report visit https://www.researchandmarkets.com/r/4mlshh

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.